Glaukos (NYSE:GKOS) Issues Earnings Results

Glaukos (NYSE:GKOS) announced its quarterly earnings results on Thursday. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02), Zacks reports. The firm had revenue of $105.50 million during the quarter, compared to the consensus estimate of $100.72 million. Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. Glaukos updated its FY 2025 guidance to EPS.

Glaukos Price Performance

Glaukos stock opened at $126.03 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71. Glaukos has a 1 year low of $83.90 and a 1 year high of $163.71. The firm has a 50-day moving average of $152.75 and a two-hundred day moving average of $139.25.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on GKOS. Morgan Stanley lowered shares of Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 price target on the stock. in a report on Monday, December 2nd. JPMorgan Chase & Co. lifted their target price on shares of Glaukos from $130.00 to $145.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Citigroup raised shares of Glaukos from a “neutral” rating to a “buy” rating and lifted their target price for the company from $132.00 to $162.00 in a research note on Wednesday, December 11th. Needham & Company LLC lifted their target price on shares of Glaukos from $149.00 to $176.00 and gave the company a “buy” rating in a research note on Friday. Finally, BTIG Research lifted their price target on shares of Glaukos from $140.00 to $149.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, one has given a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $163.25.

Insider Buying and Selling at Glaukos

In other news, Director Gilbert H. Kliman sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $150.28, for a total value of $1,502,800.00. Following the completion of the sale, the director now owns 32,336 shares of the company’s stock, valued at approximately $4,859,454.08. This represents a 23.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Joseph E. Gilliam sold 3,328 shares of the company’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $149.85, for a total transaction of $498,700.80. Following the completion of the sale, the chief operating officer now directly owns 102,169 shares of the company’s stock, valued at $15,310,024.65. The trade was a 3.15 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 18,744 shares of company stock valued at $2,792,151 in the last three months. Company insiders own 6.40% of the company’s stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.